Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

AstraZeneca
Boehringer Ingelheim
Baxter
Harvard Business School
Johnson and Johnson
Mallinckrodt

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NAPABUCASIN

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Napabucasin

Trial ID Title Status Sponsor Phase Summary
NCT01325441 A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Recruiting Boston Biomedical, Inc Phase 1/Phase 2 This is an open label, single arm phase 1 dose escalation study and phase 2 study of BBI608 in combination with paclitaxel in patients with advanced malignancies.
NCT01776307 A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer Recruiting Boston Biomedical, Inc Phase 2 This is an open label, multi-center, Phase 2 study of BBI608 in combination with cetuximab, panitumumab or capecitabine in patients with advanced colorectal cancer.
NCT02024607 A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Recruiting Boston Biomedical, Inc Phase 1/Phase 2 This is an open label, multi-center, Phase 1/2 dose escalation study of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib, or irinotecan.
NCT02178956 A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer Active, not recruiting Boston Biomedical, Inc Phase 3 The purpose of this study is to find out whether it is better to receive a new drug, BBI608, in addition to paclitaxel chemotherapy or better to receive paclitaxel chemotherapy alone as second line treatment for gastric and gastroesophageal junction cancer after prior first line platinum and fluoropyrimidine based chemotherapy.
NCT02231723 A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer Recruiting Boston Biomedical, Inc Phase 1 This is an open label, multi-center, multi-arm, dose-escalation study of BBI608 administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or MM-398 with 5-FU and leucovorin.
NCT02279719 A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma Recruiting Boston Biomedical, Inc Phase 1/Phase 2 This is an open label, three-arm, phase 1 dose escalation study and phase 2 study of BBI608 in combination with sorafenib, or BBI503 in combination with sorafenib. The study population is adult patients with advanced hepatocellular carcinoma who have not received systemic chemotherapy.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for Napabucasin

Condition Name

Condition Name for
Intervention Trials
Cancer 3
Colorectal Cancer 2
Gastric Cancer 1
Metastatic Colorectal Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Colorectal Neoplasms 5
Pancreatic Neoplasms 2
Adenocarcinoma 2
Gastrointestinal Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Napabucasin

Trials by Country

Trials by Country for
Location Trials
United States 96
Japan 21
China 18
Australia 9
Brazil 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for
Location Trials
Indiana 7
Texas 7
Colorado 6
Ohio 5
New York 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Napabucasin

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 6
Phase 2 2
Phase 1/Phase 2 6
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Recruiting 13
Active, not recruiting 2
Completed 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Napabucasin

Sponsor Name

Sponsor Name for
Sponsor Trials
Boston Biomedical, Inc 15
1Globe Biomedical Co., Ltd. 2
Sumitomo Dainippon Pharma Co., Ltd. 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 18
Other 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Merck
AstraZeneca
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.